001     182524
005     20240229145721.0
024 7 _ |a 10.1080/10543406.2021.2011905
|2 doi
024 7 _ |a 1054-3406
|2 ISSN
024 7 _ |a 1520-5711
|2 ISSN
037 _ _ |a DKFZ-2022-02716
082 _ _ |a 610
100 1 _ |a Zocholl, Dario
|0 0000-0002-9218-6919
|b 0
245 _ _ |a On the feasibility of pediatric dose-finding trials in small samples with information from a preceding trial in adults
260 _ _ |a Philadelphia, PA
|c 2022
|b Taylor & Francis
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1668164883_5814
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C060#
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Wiesenfarth, Manuel
|0 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
|b 1
|u dkfz
700 1 _ |a Rauch, Geraldine
|0 0000-0002-2451-1660
|b 2
700 1 _ |a Kopp-Schneider, Annette
|0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.1080/10543406.2021.2011905
|g Vol. 32, no. 5, p. 652 - 670
|0 PERI:(DE-600)2008925-9
|n 5
|p 652 - 670
|t Journal of biopharmaceutical statistics
|v 32
|y 2022
|x 1054-3406
909 C O |o oai:inrepo02.dkfz.de:182524
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J BIOPHARM STAT : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 2 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21